Of the two well-known rodent models of human type 1 diabetes (the non-obese diabetic mouse and the BioBreeding rat) the mouse has become the model of choice. Here the authors re-examine the value ...
Another underused model resource is the set of spontaneous ... Are there differences in the pathogenesis and response to therapy of mouse diabetes disease models with an acute onset versus those ...
distasonis peptide and that P. distasonis can enhance type 1 diabetes development in the the mouse model, we have to prove that this enhancement is directly related to the peptide,” Altindis said. To ...
Diabetes affects the body's ability to control ... labs together to perform a study with antibiotics in a diabetic mouse model of S. aureus infection. First, the team prepared a mouse model ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss., ...
Updated results from BP1001-A obesity and Type 2 diabetes testing from the second stage of pre-clinical testing are as follows: Previously, Bio-Path reported BP1001-A increased insulin sensitivity in ...
These data show BP1001-A has increased potential as a treatment for obese patients who have Type 2 diabetes. In the final step of pre-clinical testing, Bio-Path will use a mouse model to assess ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
These data show BP1001-A has increased potential as a treatment for obese patients who have Type 2 diabetes. In the final step of pre-clinical testing, Bio-Path will use a mouse model to assess ...